122 related articles for article (PubMed ID: 18384543)
1. An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum.
Foss CE; Clark AR; Inabinet R; Camacho F; Jorizzo JL
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):943-9. PubMed ID: 18384543
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study.
Huang PH; Liao YH; Wei CC; Tseng YH; Ho JC; Tsai TF
J Eur Acad Dermatol Venereol; 2008 Aug; 22(8):923-30. PubMed ID: 18312328
[TBL] [Abstract][Full Text] [Related]
3. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults.
Moul DK; Routhouska SB; Robinson MR; Korman NJ
J Am Acad Dermatol; 2008 Jun; 58(6):984-9. PubMed ID: 18395294
[TBL] [Abstract][Full Text] [Related]
4. A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response.
Lui H; Gulliver W; Tan J; Hong CH; Hull P; Shear NH; Paradiso-Hardy F; Bissonette R
J Drugs Dermatol; 2012 Aug; 11(8):929-37. PubMed ID: 22859237
[TBL] [Abstract][Full Text] [Related]
5. Alefacept for erosive lichen planus: a case series.
Chang AL; Badger J; Rehmus W; Kimball AB
J Drugs Dermatol; 2008 Apr; 7(4):379-83. PubMed ID: 18459520
[TBL] [Abstract][Full Text] [Related]
6. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study.
Mease PJ; Reich K;
J Am Acad Dermatol; 2009 Mar; 60(3):402-11. PubMed ID: 19028407
[TBL] [Abstract][Full Text] [Related]
7. Failure of alefacept in the treatment of vitiligo.
Bin Dayel S; AlGhamdi K
J Drugs Dermatol; 2013 Feb; 12(2):159-61. PubMed ID: 23377387
[TBL] [Abstract][Full Text] [Related]
8. Psoriasis responds to intralesional injections of alefacept and may predict systemic response to intramuscular alefacept: interim results of a single-arm, open-label study.
Gattu S; Busse K; Bhutani T; Chiang C; Nguyen T; Becker E; Koo JY
J Dermatolog Treat; 2012 Apr; 23(2):103-8. PubMed ID: 21254875
[TBL] [Abstract][Full Text] [Related]
9. An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis.
Ortonne JP; Khemis A; Koo JY; Choi J
J Eur Acad Dermatol Venereol; 2005 Sep; 19(5):556-63. PubMed ID: 16164708
[TBL] [Abstract][Full Text] [Related]
10. An open-label pilot study of apremilast for the treatment of moderate to severe lichen planus: a case series.
Paul J; Foss CE; Hirano SA; Cunningham TD; Pariser DM
J Am Acad Dermatol; 2013 Feb; 68(2):255-61. PubMed ID: 22910104
[TBL] [Abstract][Full Text] [Related]
11. Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series.
Shah A; O'Neill J; Feldman SR
J Drugs Dermatol; 2010 Dec; 9(12):1491-4. PubMed ID: 21120256
[TBL] [Abstract][Full Text] [Related]
12. Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis.
Perlmutter A; Cather J; Franks B; Jaracz E; Menter A
J Am Acad Dermatol; 2008 Jan; 58(1):116-24. PubMed ID: 17997502
[TBL] [Abstract][Full Text] [Related]
13. Canakinumab in adults with steroid-refractory pyoderma gangrenosum.
Kolios AG; Maul JT; Meier B; Kerl K; Traidl-Hoffmann C; Hertl M; Zillikens D; Röcken M; Ring J; Facchiano A; Mondino C; Yawalkar N; Contassot E; Navarini AA; French LE
Br J Dermatol; 2015 Nov; 173(5):1216-23. PubMed ID: 26471257
[TBL] [Abstract][Full Text] [Related]
14. The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis.
Roberts JL; Ortonne JP; Tan JK; Jaracz E; Frankel E;
J Am Acad Dermatol; 2010 Jun; 62(6):968-78. PubMed ID: 20392521
[TBL] [Abstract][Full Text] [Related]
15. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis.
Krueger GG; Gottlieb AB; Sterry W; Korman N; Van De Kerkhof P
J Dermatolog Treat; 2008; 19(3):146-55. PubMed ID: 18569270
[TBL] [Abstract][Full Text] [Related]
16. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.
Brooklyn TN; Dunnill MG; Shetty A; Bowden JJ; Williams JD; Griffiths CE; Forbes A; Greenwood R; Probert CS
Gut; 2006 Apr; 55(4):505-9. PubMed ID: 16188920
[TBL] [Abstract][Full Text] [Related]
17. Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis.
Moul DK; Routhouska SB; Korman NJ
J Cutan Med Surg; 2007; 11(4):132-6. PubMed ID: 17601420
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of alefacept in elderly patients and other special populations.
Gottlieb AB; Boehncke WH; Darif M
J Drugs Dermatol; 2005; 4(6):718-24. PubMed ID: 16302557
[TBL] [Abstract][Full Text] [Related]
19. The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis.
Langewouters AM; Bovenschen HJ; De jong EM; Van Erp PE; Van De Kerkhof PC
J Dermatolog Treat; 2007; 18(5):279-85. PubMed ID: 17852631
[TBL] [Abstract][Full Text] [Related]
20. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis.
Lebwohl M; Christophers E; Langley R; Ortonne JP; Roberts J; Griffiths CE;
Arch Dermatol; 2003 Jun; 139(6):719-27. PubMed ID: 12810502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
